RxDoctor Payments Data

George Lin

Pulmonary Disease · Emerson, NJNPI 1518927474

Payments from drug & device makers

$8,459in general payments, 2019–2025

Across 492 payments — averaging $17.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AstraZeneca$1K
  • Sanofi$739
  • Insmed, Inc.$555
  • Philips North America LLC$427
  • Boehringer Ingelheim$392
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$8,17497%
  • Education$2843%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,459 in reported general payments places this provider in the 75th percentile of 472 pulmonary disease providers in New Jersey.

See all pulmonary disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$277,609
Medicare patients
689
Services billed
2,128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter242$202,076
Breo ElliptaFluticasone/Vilanterol88$45,017
Breztri AerosphereBudesonide/Glycopyr/Formoterol51$41,134
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr54$37,793
EliquisApixaban37$32,492
Spiriva RespimatTiotropium Bromide41$26,678
Incruse ElliptaUmeclidinium Bromide42$21,522
OzempicSemaglutide12$19,125
DuleraMometasone/Formoterol47$19,053
Stiolto RespimatTiotropium Br/Olodaterol Hcl24$18,050
Spiriva HandihalerTiotropium Bromide25$14,928
Fluticasone-SalmeterolFluticasone Propion/Salmeterol70$13,436
Arnuity ElliptaFluticasone Furoate31$11,297
Albuterol Sulfate HfaAlbuterol Sulfate267$9,201
SymbicortBudesonide/Formoterol Fumarate22$6,931

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$1,466$317,705457 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,066$48,06573 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$392$44,72865 claims
PfizerEliquis$40$32,49237 claims
MerckDulera$88$19,05347 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 472 pulmonary disease providers in New Jersey.

Other pulmonary disease in Emerson

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →